ProQR Therapeutics N.V. logo
ProQR Therapeutics N.V. PRQR
$ 4.07 2.26%

Annual report 2023
added 11-09-2024

report update icon

ProQR Therapeutics N.V. Balance Sheet 2011-2024 | PRQR

Annual Balance Sheet ProQR Therapeutics N.V.

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-171 M -58.4 M -98.7 M -96.2 M -40.9 M -53.5 M -90 M -110 M -589 K -153 K -

Long Term Debt

- - 14.7 M 16.2 M 12.7 M 9.39 M 5.28 M 5.7 M 4.82 M 2.81 M 943 K 96 K -

Long Term Debt Current

1.61 M 1.39 M 1.53 M 1.26 M 508 K - - - - - - - -

Total Non Current Liabilities

- - - 31.9 M 12.7 M 9.39 M 5.28 M 5.7 M 4.82 M 2.83 M 991 K 96 K -

Total Current Liabilities

- - - - - - - - - - - - -

Total Liabilities

96.5 M 106 M 96.4 M 42.2 M 23.7 M 17.5 M 13.8 M 12.4 M 10.3 M 5.84 M 4.59 M 239 K -

Deferred Revenue

- - - 700 K 711 K 545 K 347 K - 144 K - - - -

Retained Earnings

- - - -258 M -212 M -155 M -119 M -75.7 M -36.6 M -15.8 M -3.67 M -418 K -

Total Assets

138 M 171 M 210 M 98.7 M 118 M 110 M 53.1 M 65.5 M 100 M 115 M 4.5 M 338 K -

Cash and Cash Equivalents

119 M 94.8 M 188 M 75.8 M 112 M 106 M 48.1 M 59.2 M 94.9 M - - - -

Book Value

41.4 M 65.1 M 113 M 56.5 M 93.8 M 92.7 M 39.3 M 53.1 M 89.8 M 109 M -89 K 99 K -

Total Shareholders Equity

- - 113 M 56.5 M 93.8 M 92.7 M 39.3 M 53.1 M 89.8 M - - - -

All numbers in EUR currency

Quarterly Balance Sheet ProQR Therapeutics N.V.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - 14.4 M 14.7 M 15.1 M 15.5 M - 15.7 M 14.7 M - - - - 609 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - 68.8 M - - - 31.9 M - - - 12.7 M - - - 9.39 M - - - 5.28 M - - - 5.7 M - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- - - 90 M 96.4 M 67.3 M 44.8 M - 42.2 M 42.1 M 13.9 M 22.3 M 23.7 M 21.6 M 20 M - 17.5 M - 14.8 M - 13.8 M - - - 12.4 M - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - - - -318 M - - - -258 M - - - -212 M - - - -155 M - - - -119 M - - - -75.7 M - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

- - - 190 M 210 M 195 M 162 M - 98.7 M 110 M 93.5 M 104 M 118 M 81.1 M 90.3 M - 110 M - 37.5 M - 53.1 M - - - 65.5 M - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - - 168 M 188 M 156 M 139 M 67.9 M 75.8 M 88.8 M 87.1 M 98.1 M 112 M 74.8 M 82.5 M 94.1 M 106 M 114 M 33 M 38 M 48.1 M - 42.3 M 52.1 M 59.2 M - - - 94.9 M - - - 113 M - - - - - - - - - - - - - - -

Book Value

- - - 100 M 113 M 128 M 118 M - 56.5 M 68.1 M 79.6 M 81.4 M 93.8 M 59.4 M 70.2 M - 92.7 M - 22.7 M - 39.3 M - - - 53.1 M - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- - - 100 M 113 M 128 M 118 M 49.2 M 56.5 M 68.1 M 79.6 M 81.4 M 93.8 M 59.4 M 70.2 M 80.8 M 92.7 M 102 M 22.7 M - 39.3 M - 36.8 M - 53.1 M - - - 89.8 M - - - 109 M - - - - - - - - - - - - - - -

All numbers in EUR currency